Victory Capital Management
PACB icon

Victory Capital Management’s Pacific Biosciences PACB Stock Holding History

Victory Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.5K Buy
33,057
+2,214
+7% +$3.22K ﹤0.01% 2388
2026
Q1 		$40.7K Sell
30,843
-341
-1% -$610 ﹤0.01% 2329
2025
Q4 		$58.3K Buy
31,184
+725
+2% +$1.39K ﹤0.01% 2316
2025
Q3 		$39K Sell
30,459
-1,040
-3% -$1.41K ﹤0.01% 2363
2025
Q2 		$39.1K Buy
31,499
+2,134
+7% +$2.46K ﹤0.01% 2401
2025
Q1 		$34.7K Sell
29,365
-546
-2% -$838 ﹤0.01% 2392
2024
Q4 		$54.7K Sell
29,911
-3,638
-11% -$7.1K ﹤0.01% 2384
2024
Q3 		$57K Sell
33,549
-580
-2% -$953 ﹤0.01% 2380
2024
Q2 		$46.8K Buy
34,129
+942
+3% +$1.9K ﹤0.01% 2374
2024
Q1 		$124K Sell
33,187
-1,061,537
-97% -$6.22M ﹤0.01% 2276
2023
Q4 		$10.7M Buy
1,094,724
+442,250
+68% +$3.62M 0.01% 1028
2023
Q3 		$5.45M Sell
652,474
-1,191,647
-65% -$13.6M 0.01% 1193
2023
Q2 		$24.5M Buy
1,844,121
+192,332
+12% +$2.34M 0.03% 694
2023
Q1 		$19.1M Buy
1,651,789
+1,628,823
+7,092% +$16.2M 0.02% 803
2022
Q4 		$188K Sell
22,966
-9
-0% -$78 ﹤0.01% 2279
2022
Q3 		$133K Buy
22,975
+2,171
+10% +$12.5K ﹤0.01% 2428
2022
Q2 		$92K Buy
20,804
+157
+0.8% +$954 ﹤0.01% 2468
2022
Q1 		$131K Sell
20,647
-10,684
-34% -$123K ﹤0.01% 2478
2021
Q4 		$641K Sell
31,331
-9,156
-23% -$221K ﹤0.01% 2034
2021
Q3 		$1.03M Buy
40,487
+2,059
+5% +$61K ﹤0.01% 1849
2021
Q2 		$1.34M Sell
38,428
-1,723
-4% -$50.1K ﹤0.01% 1778
2021
Q1 		$1.34M Buy
40,151
+2,312
+6% +$80.9K ﹤0.01% 1773
2020
Q4 		$982K Buy
37,839
+11,440
+43% +$194K ﹤0.01% 1791
2020
Q3 		$261K Buy
26,399
+2,308
+10% +$13.3K ﹤0.01% 2206
2020
Q2 		$83K Sell
24,091
-579
-2% -$1.97K ﹤0.01% 2368
2020
Q1 		$75K Sell
24,670
-7,111
-22% -$29.1K ﹤0.01% 2398
2019
Q4 		$163K Sell
31,781
-961
-3% -$4.88K ﹤0.01% 2369
2019
Q3 		$169K Buy
+32,742
New +$183K ﹤0.01% 2271
2018
Q4 		– Sell
-300,000
Closed -$1.62M – 1805
2018
Q3 		$1.62M Buy
+300,000
New +$1.29M ﹤0.01% 1143

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Victory Capital Management's PACB Position: Q2 2026 in Review

Victory Capital Management increased its Pacific Biosciences (PACB) stake by 7.2% in Q2 2026, buying an estimated $3.22K and bringing the position to 33,057 shares worth $55.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2388.

Victory Capital Management first reported a position in PACB in Q3 2018 and has held it in 29 quarters since. The position peaked at $24.5M in Q2 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Victory Capital Management held 33,057 shares of Pacific Biosciences worth $55.5K as of Q2 2026.
  • Victory Capital Management bought 2,214 Pacific Biosciences shares in Q2 2026, an estimated $3.22K.
  • Pacific Biosciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2388 holding.
  • Victory Capital Management first reported a position in Pacific Biosciences in Q3 2018 and has held it in 29 quarters since.
  • Victory Capital Management's Pacific Biosciences position peaked at $24.5M in Q2 2023.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.